CN110897159B - 一种预防或治疗关节疾病的组合物 - Google Patents
一种预防或治疗关节疾病的组合物 Download PDFInfo
- Publication number
- CN110897159B CN110897159B CN201911263554.XA CN201911263554A CN110897159B CN 110897159 B CN110897159 B CN 110897159B CN 201911263554 A CN201911263554 A CN 201911263554A CN 110897159 B CN110897159 B CN 110897159B
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- ginseng
- joint
- cartilage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 208000012659 Joint disease Diseases 0.000 title claims abstract description 37
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 51
- 210000000845 cartilage Anatomy 0.000 claims abstract description 48
- 239000000843 powder Substances 0.000 claims abstract description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 32
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 30
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 30
- 235000008434 ginseng Nutrition 0.000 claims abstract description 30
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 25
- 102000008186 Collagen Human genes 0.000 claims abstract description 24
- 108010035532 Collagen Proteins 0.000 claims abstract description 24
- 229920001436 collagen Polymers 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 21
- 241000208689 Eucommia ulmoides Species 0.000 claims abstract description 20
- 235000009467 Carica papaya Nutrition 0.000 claims abstract description 19
- 241000270273 Ptyas dhumnades Species 0.000 claims abstract description 16
- 241000209205 Coix Species 0.000 claims abstract description 11
- 238000001035 drying Methods 0.000 claims description 19
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 19
- 235000013336 milk Nutrition 0.000 claims description 19
- 239000008267 milk Substances 0.000 claims description 19
- 210000004080 milk Anatomy 0.000 claims description 19
- 239000011707 mineral Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 241000219173 Carica Species 0.000 claims description 18
- 244000077995 Coix lacryma jobi Species 0.000 claims description 15
- 210000002969 egg yolk Anatomy 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 14
- 102000002322 Egg Proteins Human genes 0.000 claims description 13
- 108010000912 Egg Proteins Proteins 0.000 claims description 13
- 235000013345 egg yolk Nutrition 0.000 claims description 13
- 241000521581 Millettia Species 0.000 claims description 12
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 6
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 241001098027 Callerya speciosa Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 33
- 210000000988 bone and bone Anatomy 0.000 abstract description 23
- 210000000629 knee joint Anatomy 0.000 abstract description 19
- 208000006820 Arthralgia Diseases 0.000 abstract description 17
- 241000283690 Bos taurus Species 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 15
- 241000251730 Chondrichthyes Species 0.000 abstract description 14
- 208000024891 symptom Diseases 0.000 abstract description 14
- 230000006870 function Effects 0.000 abstract description 12
- 241000180649 Panax notoginseng Species 0.000 abstract description 10
- 235000003143 Panax notoginseng Nutrition 0.000 abstract description 10
- 210000002435 tendon Anatomy 0.000 abstract description 10
- 210000000582 semen Anatomy 0.000 abstract description 9
- 238000005728 strengthening Methods 0.000 abstract description 9
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 8
- 230000003213 activating effect Effects 0.000 abstract description 5
- 210000003734 kidney Anatomy 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 5
- 206010023230 Joint stiffness Diseases 0.000 abstract description 4
- 238000005299 abrasion Methods 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 240000006432 Carica papaya Species 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- 201000008482 osteoarthritis Diseases 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 206010003246 arthritis Diseases 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 238000002156 mixing Methods 0.000 description 8
- 230000008439 repair process Effects 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 208000001132 Osteoporosis Diseases 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 241000208688 Eucommia Species 0.000 description 6
- 210000001188 articular cartilage Anatomy 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000000963 osteoblast Anatomy 0.000 description 6
- 241000628997 Flos Species 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000008468 bone growth Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 210000002997 osteoclast Anatomy 0.000 description 5
- 210000001258 synovial membrane Anatomy 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 4
- 230000037182 bone density Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 210000002437 synoviocyte Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 229940059329 chondroitin sulfate Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229930182494 ginsenoside Natural products 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 208000018937 joint inflammation Diseases 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002363 skeletal muscle cell Anatomy 0.000 description 3
- 201000004595 synovitis Diseases 0.000 description 3
- QCBCPALLWXTPLW-SFHVURJKSA-N (2S)-2-(3,4-dihydroxyphenyl)-8,8-dimethyl-2,3,9,10-tetrahydropyrano[2,3-h]chromen-4-one Chemical compound C1([C@@H]2CC(=O)C=3C=CC4=C(C=3O2)CCC(O4)(C)C)=CC=C(O)C(O)=C1 QCBCPALLWXTPLW-SFHVURJKSA-N 0.000 description 2
- 208000036487 Arthropathies Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 241000252230 Ctenopharyngodon idella Species 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 206010060820 Joint injury Diseases 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000008558 Osteophyte Diseases 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 201000010934 exostosis Diseases 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 201000010930 hyperostosis Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- -1 iridoid glycoside compound Chemical class 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000011764 rheumatoid arthritis animal model Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 229910021487 silica fume Inorganic materials 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明属于食品领域,公开了一种预防或治疗关节疾病的组合物,所述组合物主要由以下原料制成:乌梢蛇、杜仲花、木瓜、薏苡、三七、牛大力、人参、软骨、糖和肽。本发明制得的组合物以乌梢蛇、杜仲花、薏苡、木瓜、三七、牛大力和人参为原料,制得的组合物整体上具有强筋活络、祛风湿止痹痛、补益肝肾和强筋健骨的作用,再配以鲨鱼软骨粉、壳寡糖和牛骨胶原蛋白肽使关节润滑,不易磨损。对关节疾病,特别是对膝关节退行性病变引起的关节疾病具有很好的预防或治疗效果,有效改善关节僵硬、酸痛等症状,长期服用,无副作用。
Description
技术领域
本发明属于食品领域,特别涉及一种预防或治疗关节疾病的组合物。
背景技术
关节退行性病变是一种以关节软骨损伤为特征的慢性、进展性的关节疾病。临床典型特征包括膝关节骨质增生、关节间隙变窄和软骨下骨质硬化等等;以行走时膝关节疼痛、晨起时关节僵硬、膝关节肿胀和活动受限为主要表现形式;可引起中老年人下肢功能障碍。
关节退行性病变的发病机理涉及多个因素,主要与关节滑膜增生、关节软骨磨损、关节炎症因子增高相关,导致关节滑膜与关节腔内的组织渗透性改变,膝关节内的代谢紊乱,最终造成膝关节滑膜、软骨及关节周围组织的病变。关节退行性病变,特别是膝关节退行性病变发病年龄随时间推移呈明显的上升趋势,40岁人群膝关节退行性病发病率约为10-17%,而60岁人群的发病率则上升到50%以上。
现代医学对关节退行性病变的认识多从关节软骨磨损、滑膜增厚、关节炎症因子分泌增加等方面入手,多采用止痛药和非甾体类抗炎药,能有效的减轻关节疼痛、僵硬等症状,但效果不佳,且长期服用副作用明显。
现有技术中也有一些中药或保健品用来预防或治疗关节疾病,但往往注重补钙和补充关节软骨营养物质,修复关节损伤,但功效单一,无法根治。现有技术中用来预防或治疗关节疾病的中药或保健品往往忽视了关节退行性病变是多因素引起的,因而预防或治疗效果不佳。
因此,希望提供一种预防或治疗关节疾病的组合物,较为全面的考虑关节退行性病变的病因,从根本上预防或治疗关节疾病,长期服用也无副作用。
发明内容
本发明旨在至少解决上述现有技术中存在的技术问题之一。为此,本发明提出一种预防或治疗关节疾病的组合物,能够很好的预防或治疗关节疾病,特别是膝关节退行性病变引起的关节疾病。本发明所述组合物修复关节软骨、改善骨质疏松、抑制关节炎症,以改善膝关节的循环状态,增强关节营养支持和物质交换,改善膝关节退行性病变症状从而对关节疾病有十分好的预防或治疗效果。
一种预防或治疗关节疾病的组合物,所述组合物主要由以下原料制成:乌梢蛇、杜仲花、木瓜、薏苡、三七、牛大力、人参、软骨、糖和肽。
优选的,所述杜仲花为杜仲雄花。
优选的,所述薏苡为薏苡仁。
优选的,所述三七为三七叶。
优选的,所述软骨为鱼软骨;进一步优选的,所述软骨为粉末状(粒径小于1mm),即为软骨粉;更优选的,所述软骨粉为鲨鱼软骨粉。
优选的,所述糖为寡糖;进一步优选的,所述寡糖为壳寡糖。
优选的,所述肽为胶原蛋白肽。
优选的,所述胶原蛋白肽是从骨中提取得到的;进一步优选的,所述胶原蛋白肽是从牛骨中提取得到的。
优选的,所述组合物还包含碱性蛋白;进一步优选的,所述组合物还包含牛初乳碱性蛋白。所述碱性蛋白补充促进骨骼修复与生长因子,促进骨骼生长。
优选的,所述组合物还包含水解蛋黄粉,所述蛋黄粉调节骨代谢,有助于骨伸长。
优选的,所述组合物还包含乳矿物盐。
优选的,所述乳矿物盐中含有的钙元素的含量为15-30%(质量分数);进一步优选的,所述乳矿物盐中含有的钙元素的含量为23%(质量分数)。
优选的,所述乳矿物盐中含有钙元素和磷元素,且钙元素和磷元素的质量比为1:(0.1-1)。
进一步优选的,所述乳矿物盐主要成分是磷酸钙。
所述乳矿物盐有助于增强骨质密度,强化骨硬度。
优选的,一种预防或治疗关节疾病的组合物,所述组合物主要由以下原料制成:乌梢蛇0.1-5份、杜仲花2-10份、木瓜4-15份、薏苡1-10份、三七2-15份、牛大力2-15份、人参0.1-5份、软骨1-10份、糖0.1-8份和肽0.1-10份。
进一步优选的,一种预防或治疗关节疾病的组合物,所述组合物主要由以下重量份的原料制成:乌梢蛇0.1-5份、杜仲花2-10份、木瓜4-15份、薏苡仁1-10份、三七叶2-15份、牛大力2-15份、人参0.1-5份、鲨鱼软骨粉1-10份、壳寡糖0.4-8份和胶原蛋白肽0.1-10份。
优选的,所述组合物还包含碱性蛋白0.1-1份。
优选的,所述组合物还包含水解蛋黄粉2-6份。
优选的,所述组合物还包含乳矿物盐1-5份。
优选的,一种预防或治疗关节疾病的组合物,所述组合物主要由以下重量份的原料制成:乌梢蛇1份、杜仲花5份、木瓜6份、薏苡3份、三七5份、牛大力8份、人参0.6份、软骨粉3份、壳寡糖2份、胶原蛋白肽2份、水解蛋黄粉4份、牛初乳碱性蛋白0.3份和乳矿物盐2.5份。
进一步优选的,一种预防或治疗关节疾病的组合物,所述组合物主要由以下重量份的原料制成:乌梢蛇1份、杜仲雄花5份、木瓜6份、薏苡仁3份、三七叶5份、牛大力8份、人参0.6份、鲨鱼软骨粉3份、壳寡糖2份、牛骨胶原蛋白肽2份、水解蛋黄粉4份、牛初乳碱性蛋白0.3份和乳矿物盐2.5份。
乌梢蛇:味甘性平,归肝经。功擅祛风湿、除顽痹、舒筋活络,用于风湿顽痹,麻木拘挛,抽搐痉挛等。乌梢蛇含有乌梢蛇Ⅱ型胶原蛋白对关节滑膜细胞的炎症因子有抑制作用,乌梢蛇的不饱和脂肪酸有抗风湿因子的作用,能有效减轻关节炎症症状。
杜仲花:杜仲有补肝肾、强筋骨的作用,杜仲花特别是杜仲雄花含有多种抗炎、抗衰老、镇痛、抗疲劳作用的有效成分。杜仲雄花含有黄酮类和多糖类成分,具有明确的抗炎、抗菌的作用,可抑制膝关节炎症;杜仲雄花的提取物可抑制末梢神经对疼痛刺激的敏感性,提高机体疼痛阈值,肩前膝关节疼痛;杜仲雄花的黄酮提取物及环烯醚萜苷化合物促进胶原蛋白的生成、加快氧自由基的清除、预防细胞内Ca2+超载,具有良好的抗衰老作用。
木瓜:舒筋化湿,用于治疗风寒湿痹的腰腿疼痛。木瓜苷有利于抑制动物模型关节炎症状,减轻关节炎的疼痛、肿胀程度;能抑制MMP-13(人基质金属蛋白酶-13)的产生、促进关节软骨蛋白聚糖、Ⅱ型胶原蛋白合成,有利于关节软骨的修复;改善关节滑膜细胞功能,抑制炎症因子的分泌,对关节炎动物模型的血液粘、聚、浓状态均有不同程度的改善作用。能有效的改善关节炎症状,促进关节损伤修复。
薏苡:薏苡特别是薏苡仁性味甘淡平,功擅利水渗湿除痹,用于风湿痹痛、筋脉拘挛,是治疗关节痹病的重要食品。薏苡仁中含有薏苡仁蛋白和挥发油,对类风湿性关节炎动物模型有减轻关节肿痛、降低血清TNF-α(肿瘤坏死因子-α)、IL-1(白细胞介素1)、IL-6(白细胞介素6)的含量,从而改善类风湿关节炎的症状的作用;薏苡仁能有效改善关节软骨和滑膜的损伤。
三七:消肿止痛,散血止血。三七叶中总皂苷能拮抗组胺、5-HT(血清素)造成的毛细血管通透性增加,对关节炎症有明显的抑制作用;有利于提高机体疼痛阈值,减轻关节疼痛。
牛大力:味甘,性平。补虚润肺,补肾固精,强筋活络。用于腰肌劳损,风湿性关节炎等筋骨疾病。牛大力提取物,特别是牛大力水提取物可增加肌糖原储备或减少运动时糖原的消耗,为机体提供更多的能量,有提高肌肉抗疲劳能力的作用;牛大力提取物有较好的抗炎效果。
人参:人参是重要的补益药,有大补元气,复脉固脱,补脾益肺,生津,安神等作用。人参中含有人参皂苷,可有效提高软骨细胞调节蛋白的表达,抑制P21基因(细胞周期蛋白依靠性激酶抑制剂表达的相关基因)表达,从而促进软骨细胞增殖,对软骨组织有着积极的修复作用;人参皂苷可抑制滑膜细胞增殖,诱导成纤维样滑膜细胞凋亡,有效抑制关节滑膜增厚;人参总皂甙能显著降低骨骼肌细胞MDA(丙二醛)含量、增强SOD(超氧化物歧化酶)活性、抑制骨骼肌细胞内钙稳态失衡和线粒体膜电位降低,减轻骨骼肌肌纤维、骨骼肌细胞线粒体和细胞核等超微结构的损伤,有明显的抗疲劳的效应,增强关节肌肉的抗疲劳能力。
软骨:软骨含有硫酸软骨素,特别是鲨鱼软骨粉含有较高含量的硫酸软骨素。硫酸软骨素可缓解关节炎引起的疼痛和肢体僵硬症状。可大量吸收滑膜中的Na+,促进骨质增长,使破坏的软骨恢复正常。
糖:特别是寡糖中的壳寡糖,壳寡糖有抗炎、抗氧化、抑制软骨细胞凋亡、增加骨密度等作用。壳寡糖通过调节TNF-α进而降低NO的含量,发挥抗炎的作用;壳寡糖能明显抑制IL-1β(白细胞介素1α和β两种类型)诱导的软骨细胞凋亡;壳寡糖能够明显降低骨关节炎滑膜、软骨组织中TNF-α的表达水平,延缓软骨的退变程度;壳寡糖可促进骨折愈合、促进成骨细胞增殖、增加骨密度等。能有效改善关节炎症状、延缓关节退变、改善骨质疏松。
肽:肽可预防骨质疏松,能有效促进人成骨细胞增殖,特别是牛骨胶原蛋白肽可有效的预防骨质疏松,能有效促进人成骨细胞增殖,刺激膝关节软骨产生胶原蛋白肽,促进膝关节软骨修复。
水解蛋黄粉:水解蛋黄粉有促进骨骼生长、抑制骨吸收的作用,通过刺激骨芽细胞,促进骨骼增长因子(例如IGF1即类胰岛素一号增长因子、TGFβ1即转化生长因子-β)的产生,促进骨骼的成长;通过抑制破骨细胞的细胞分裂因子的分泌(如:IL-1、IL-6、TNF-α),维持骨骼成分的平衡,抑制钙的过度流失,改善骨质疏松。
碱性蛋白:碱性蛋白具有抑制破骨细胞活动,促进造骨细胞数量增加及提高活跃度的作用,特别是牛初乳碱性蛋白,具有更好的抑制破骨细胞活动,促进造骨细胞数量增加及提高活跃度的作用,通过活化造骨细胞并抑制破骨细胞运动,使钙质被有效吸收,减少流失,促进骨骼健康。
乳矿物盐:乳矿物盐具有钙强化功能,增强骨密度,有利于改善骨质疏松。
所述乌梢蛇和杜仲花,配以薏苡、木瓜、三七、牛大力和人参整体上具有强筋活络、祛风湿止痹痛、补益肝肾和强筋健骨的作用。
所述鲨鱼软骨粉、壳寡糖和牛骨胶原蛋白肽可以使关节润滑,不易磨损。
水解蛋黄粉、碱性蛋白和乳矿物盐可进一步修复骨骼缺陷,强化骨硬度。
除乌梢蛇、杜仲花、木瓜、薏苡、三七、牛大力、人参外,其他制备所用原料为属于功能因子。
一种预防或治疗关节疾病的组合物的制备方法,包括以下步骤:
将原料乌梢蛇、杜仲花、木瓜、薏苡、三七、牛大力、人参和软骨分别进行溶剂煎煮,过滤,浓缩滤液,干燥,获得粉末,然后加入剩余组分,混合,制得所述组合物。
具体的,一种预防或治疗关节疾病的组合物的制备方法,包括以下步骤:
将原料乌梢蛇、杜仲花、木瓜、薏苡、三七、牛大力、人参和软骨粉分别进行溶剂煎煮,过滤,浓缩滤液,干燥,获得粉末,然后加入糖和肽,混合,制粒,干燥,制得所述组合物;
或,将原料乌梢蛇、杜仲花、木瓜、薏苡、三七、牛大力、人参和软骨粉分别进行溶剂煎煮,过滤,浓缩滤液,干燥,获得粉末,然后加入糖和肽,再加入水解蛋黄粉、碱性蛋白或乳矿物盐中的至少一种,混合,制粒,干燥,制得所述组合物。
优选的,所述溶剂为水。
优选的,所述溶剂的加入量为原料乌梢蛇、杜仲花、木瓜、薏苡、三七、牛大力、人参或软骨粉质量的2-12倍。
优选的,所述煎煮的次数为1-3次,煎煮后获得滤液,将滤液合并,浓缩。
优选的,所述煎煮的温度为90-120℃。
优选的,混合的搅拌速度为50-200转/分钟,搅拌的时间为10-30分钟。
优选的,所述干燥的过程采用热风干燥,所述热风的温度为60-90℃。
优选的,所述组合物中水的质量分数为小于等于7%。
优选的,所述干燥步骤后,还有包装过程。
一种预防或治疗关节病的食品,包括本发明所述的组合物。
优选的,所述食品还包含辅料。
优选的,所述辅料选自乳糖、纤维素或硅胶中的至少一种。
优选的,所述食品的剂型包括片剂、胶囊或颗粒剂中的至少一种。
相对于现有技术,本发明的有益效果如下:
(1)本发明所述组合物中以乌梢蛇、杜仲花、薏苡、木瓜、三七、牛大力和人参为原料,制得的组合物整体上具有强筋活络、祛风湿止痹痛、补益肝肾和强筋健骨的作用,鲨鱼软骨粉、壳寡糖和牛骨胶原蛋白肽可使关节润滑,不易磨损。对关节疾病,特别是对膝关节退行性病变引起的关节疾病具有很好的预防或治疗效果。
(2)本发明所述组合物中还含有水解蛋黄粉、碱性蛋白和乳矿物盐可进一步修复骨骼缺陷,强化骨硬度,所述组合物可修复关节软骨、改善骨质疏松、抑制关节炎症,通过改善膝关节的循环状态,增强关节营养支持和物质交换,改善膝关节退行性病变症状从而对关节疾病有十分好的预防或治疗效果,长期服用,无副作用,另外,本发明所述组合物可以当成食品食用,对预防关节疾病有很好的效果。
(3)本发明所述组合物功效齐全,集中修复膝关节软骨损伤、抑制滑膜增厚、抑制破骨细胞分裂因子分泌,有效改善关节僵硬、酸痛等症状。
具体实施方式
为了让本领域技术人员更加清楚明白本发明所述技术方案,现列举以下实施例进行说明。需要指出的是,以下实施例对本发明要求的保护范围不构成限制作用。
实施例1
一种预防或治疗关节疾病的组合物,所述组合物主要由以下重量份的原料制成:乌梢蛇1份、杜仲雄花5份、木瓜6份、薏苡仁3份、三七叶5份、牛大力8份、人参0.6份、鲨鱼软骨粉1份、壳寡糖0.4份和胶原蛋白肽0.3份。
一种预防或治疗关节疾病的组合物的制备方法,包括以下步骤:
称取各原料,将乌梢蛇、杜仲雄花、木瓜、薏苡仁、三七叶、牛大力、人参和鲨鱼软骨粉分别用8倍质量的水,在100℃下煎煮2-4小时,过滤,获得滤液,浓缩滤液,用80℃的热风进行干燥,获得粉末,然后加入壳寡糖和胶原蛋白肽,搅拌混合,搅拌的速度为100转/分钟,搅拌10分钟,制粒,干燥,制得组合物。
制得的组合物中水分质量分数小于7%。
实施例2
一种预防或治疗关节疾病的组合物,所述组合物主要由以下重量份的原料制成:乌梢蛇1份、杜仲雄花5份、木瓜6份、薏苡仁3份、三七叶5份、牛大力8份、人参0.6份、鲨鱼软骨粉3份、壳寡糖2份、胶原蛋白肽2份、水解蛋黄粉4份、牛初乳碱性蛋白0.3份和乳矿物盐2.5份。
一种预防或治疗关节疾病的组合物的制备方法,包括以下步骤:
称取各原料,将乌梢蛇、杜仲雄花、木瓜、薏苡仁、三七叶、牛大力、人参和鲨鱼软骨粉分别用10倍质量的水,在100℃下煎煮3小时,过滤,获得滤液,浓缩滤液,用90℃的热风进行干燥,获得粉末,然后加入壳寡糖和胶原蛋白肽,再加入水解蛋黄粉、牛初乳碱性蛋白和乳矿物盐搅拌混合,搅拌的速度为60转/分钟,搅拌15分钟,制粒,干燥,制得组合物。
制得的组合物中水分质量分数小于7%。
实施例3
一种预防或治疗关节疾病的组合物,所述组合物主要由以下重量份的原料制成:乌梢蛇0.1份、杜仲花8份、木瓜4份、薏苡10份、三七2份、牛大力10份、人参0.1份、草鱼软骨粉8份、壳寡糖6份和胶原蛋白肽6份。
一种预防或治疗关节疾病的组合物的制备方法,包括以下步骤:
将原料乌梢蛇、杜仲花、木瓜、薏苡、三七、牛大力、人参和草鱼软骨粉分别用6倍质量的水煎煮,过滤,取滤液,浓缩滤液,采用70℃的热风进行干燥,获得粉末,然后加入壳寡糖和胶原蛋白肽,混合,制粒,干燥,制得组合物。
制得的组合物中水分质量分数小于7%。
实施例4
一种预防或治疗关节疾病的组合物,所述组合物主要由以下重量份的原料制成:乌梢蛇4份、杜仲花2份、木瓜12份、薏苡1份、三七8份、牛大力2份、人参0.1份、软骨粉3份、壳寡糖7份和胶原蛋白肽1份。
一种预防或治疗关节疾病的组合物的制备方法,包括以下步骤:
将原料乌梢蛇、杜仲花、木瓜、薏苡、三七、牛大力、人参和软骨粉分别用6倍质量的水煎煮,过滤,取滤液,浓缩滤液,采用80℃的热风进行干燥,获得粉末,然后加入壳寡糖和胶原蛋白肽,混合,制粒,干燥,制得组合物。
制得的组合物中水分质量分数小于7%。
实施例5
与实施例3相比,实施例5的组合物主要由以下重量份的原料制成:乌梢蛇0.5份、杜仲雄花10份、木瓜4份、薏苡10份、三七叶2份、牛大力10份、人参0.1份、鲨鱼软骨粉8份、壳寡糖4份、胶原蛋白肽4份和牛初乳碱性蛋白0.4份。其余制备过程与实施例3相同。
实施例6
与实施例3相比,实施例5的组合物主要由以下重量份的原料制成:乌梢蛇0.8份、杜仲花6份、木瓜3份、薏苡仁8份、三七2份、牛大力8份、人参0.2份、鲨鱼软骨粉8份、壳寡糖4份、胶原蛋白肽4份、水解蛋黄粉1份。其余制备过程与实施例3相同。
对比例1
与实施例2相比,对比例1制得的组合物不含有的原料为鲨鱼软骨粉、壳寡糖、胶原蛋白肽、水解蛋黄粉、牛初乳碱性蛋白和乳矿物盐。其余组分与实施例2相同,且制备过程相同。
产品效果测试
膝骨关节炎诊断标准参照国家中医药管理局1994年出版的《中医病证诊断疗效标准》的诊断标准:根据临床表现、体格检查、X片检查等资料综合分析确定。①近一个月内经常反复膝关节疼痛;②X线(站立或负重位):关节间隙变窄、软骨骨硬化或囊性变、关节缘骨赘形成;③中老年者(≥40岁);④晨僵≤30min;⑤活动时有摩擦音。
综合临床及X线检查,符合①、②或①、③、④、⑤即可诊断为膝OA(骨性关节炎)。病情X线影像分级标准:0级为正常;Ⅰ级为仅有骨刺产生或可疑关节间隙狭窄;Ⅱ级为肯定有骨刺,关节间隙变窄(少于正常关节间隙的1/2);Ⅲ级为多处有骨刺,关节间隙变窄(多于正常关节间隙的1/2);V级为大的骨刺,关节间隙消失,或明显骨端变形,或轻度骨磨损(小于1cm)。
随机选取符合上述膝骨关节炎患者120例,取实施例2-3和对比例1制得的组合物,口服2个疗程(2个月),每日2次,早晚各一次,另设置一空白对照组,服用安慰剂。实验结束后,进行如下指标评价:
1.有效率评价
参照2002年版《中药新药临床研究指导原则》制订的膝骨关节炎患者疗效评价标准。痊愈:症状体征消失,关节活动功能恢复正常;显效:症状体征明显改善,关节活动不受限,能参加正常活动和工作;有效:疼痛等症状基本消失,关节活动轻度受限;无效:症状体征未见明显改善。总有效率=[(痊愈人数+显效人数+有效人数)/30]*100%,结果如表1所示。
表1:
从表1可以看出。治疗2个月后,服用实施例2和实施例3的组合物的总有效率为93.3%和90.0%,明显优于对比例1和空白对照组的效果。说明本发明实施例制得的组合物有好的缓解膝骨关节炎的关节不适症状的作用。
根据上述2个月的治疗结果,统计治疗前后各实验组的临床指标(疼痛、僵硬、功能(功能指关节活动功能))的WOMAC指数(骨性关节炎指数)及总WOMAC指数(总WOMAC为疼痛、僵硬、功能的总和),结果如表2所示。
表2:
备注:*表示p小于0.05,有显著性差异,**表示p小于0.01,有极显著性差异。
治疗前,四个组(实施例2组、实施例3组、对比例1组和空白对照组)患者的疼痛、僵硬、功能及总WOMAC指数并无明显差异(p>0.05);治疗2个月后,实施例2组和实施例3组患者的疼痛、僵硬、功能及总WOMAC指数均较治疗前明显降低(p<0.01),且均优于对比例1组和空白对照组,说明本发明制得的组合物治疗膝骨关节炎效果明显,能有效缓解关节局部疼痛,改善关节功能,提高生活质量。
实施例7
一种预防或治疗关节病的食品,按重量份数计,包括实施例2制得的组合物20份,乳糖15份、微晶纤维素2份、微粉硅胶0.5份。
一种预防或治疗关节病的食品的制备方法:
称取上述组分,以300转/分钟的搅拌速度混合10分钟,获得混合物,通过热风干燥控制混合物的水分为3-5%(质量分数),然后压片,制得食品,然后包装,检验,出库。
制得的食品为片剂。
实施例8
一种预防或治疗关节病的食品,按重量份数计,包括实施例3制得的组合物40份,微晶纤维素3份、微粉硅胶1份。
一种预防或治疗关节病的食品的制备方法:
称取上述组分,以250转/分钟的搅拌速度混合10分钟,获得混合物,通过热风干燥控制混合物的水分小于等于9%(质量分数),然后制粒,制得食品,然后装胶囊,包装,检验,出库。
制得的食品为胶囊。
Claims (4)
1.一种预防或治疗关节疾病的组合物,其特征在于,所述组合物由以下原料制成:乌梢蛇0.1-5份、杜仲花2-10份、木瓜4-15份、薏苡1-10份、三七2-15份、牛大力2-15份、人参0.1-5份、软骨1-10份、壳寡糖0.4-8份和胶原蛋白肽0.1-10份;
所述的组合物的制备方法,其特征在于,将原料乌梢蛇、杜仲花、木瓜、薏苡、三七、牛大力、人参和软骨分别进行溶剂煎煮,过滤,浓缩滤液,干燥,获得粉末,然后加入剩余组分,混合,制得所述组合物。
2.根据权利要求1所述的组合物,其特征在于,所述杜仲花为杜仲雄花;所述软骨为鱼软骨。
3.根据权利要求1所述的组合物,其特征在于,所述组合物还包含碱性蛋白、水解蛋黄粉或乳矿物盐中的至少一种。
4.根据权利要求3所述的组合物,其特征在于,所述组合物由以下重量份的原料制成:乌梢蛇1份、杜仲花5份、木瓜6份、薏苡3份、三七5份、牛大力8份、人参0.6份、软骨3份、壳寡糖糖2份、胶原蛋白肽2份、水解蛋黄粉4份、碱性蛋白0.3份和乳矿物盐2.5份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911263554.XA CN110897159B (zh) | 2019-12-11 | 2019-12-11 | 一种预防或治疗关节疾病的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911263554.XA CN110897159B (zh) | 2019-12-11 | 2019-12-11 | 一种预防或治疗关节疾病的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110897159A CN110897159A (zh) | 2020-03-24 |
CN110897159B true CN110897159B (zh) | 2024-02-20 |
Family
ID=69824277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911263554.XA Active CN110897159B (zh) | 2019-12-11 | 2019-12-11 | 一种预防或治疗关节疾病的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110897159B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111387397A (zh) * | 2020-04-15 | 2020-07-10 | 湖北瑞邦生物科技有限公司 | 一种改善骨胳的牛骨肽饮品及其制备方法 |
CN115500513A (zh) * | 2022-10-20 | 2022-12-23 | 洛阳清奇古怪生物科技有限公司 | 一种针对关节保护的组合配方 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104740425A (zh) * | 2015-03-03 | 2015-07-01 | 成都岷江源药业有限公司 | 一种治疗风湿痹症的药物组合物及其制备方法和用途 |
CN108144047A (zh) * | 2017-12-30 | 2018-06-12 | 广州润虹医药科技股份有限公司 | 一种增加骨密度的含壳聚糖的保健组合物及其用途 |
-
2019
- 2019-12-11 CN CN201911263554.XA patent/CN110897159B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104740425A (zh) * | 2015-03-03 | 2015-07-01 | 成都岷江源药业有限公司 | 一种治疗风湿痹症的药物组合物及其制备方法和用途 |
CN108144047A (zh) * | 2017-12-30 | 2018-06-12 | 广州润虹医药科技股份有限公司 | 一种增加骨密度的含壳聚糖的保健组合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN110897159A (zh) | 2020-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104431684A (zh) | 一种增加骨密度的保健品及其制备方法 | |
CN109758571A (zh) | 一种促进尿酸代谢、改善痛风、保护关节的组合物及其制备方法 | |
CN110897159B (zh) | 一种预防或治疗关节疾病的组合物 | |
CN104206949A (zh) | 改善骨质疏松、增加骨密度的组合物、其制备方法及其在制备保健品上的应用 | |
CN108618126A (zh) | 一种中药复方减肥特殊膳食食品及其制备方法 | |
US10758580B2 (en) | Composition of sea buckthorn pulp oil and panax notoginseng saponins for treating osteoporotic fracture and/or osteoarthritis and uses thereof | |
CN108112997B (zh) | 一种保健食品组合物 | |
CN106421757A (zh) | 一种辅助治疗痛风和增加骨密度的组合物及其应用 | |
WO2016000508A1 (zh) | 一种治疗痛风症的中药制剂及其制备方法 | |
CN103656626B (zh) | 一种中老年治骨养骨复方络合钙制剂及其制备方法 | |
CN104116022A (zh) | 用于改善妇女更年期综合症的复合保健食品及其制备方法 | |
CN104225417A (zh) | 一种辅助改善记忆力功能的中药组合物及其制备方法 | |
CN109170916A (zh) | 一种强身健体食品组合物及其制备方法 | |
CN105943958A (zh) | 一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法 | |
CN114365850A (zh) | 一种具有改善软骨健康的多肽组合物及其制备方法 | |
CN102626463A (zh) | 一种增加骨密度、防治骨质疏松症的天然药物组合物 | |
CN104523804B (zh) | 一种增加骨密度的胶囊及其制备方法 | |
CN109381491B (zh) | 一种防治骨质疏松的组合物及其制备方法和应用 | |
CN107212158A (zh) | 一种防治母猪裂蹄症的营养强化保健型预混料 | |
CN103860430B (zh) | 一种美容面膜及其制备方法 | |
CN106974992A (zh) | 一种增加骨密度的组合物及其应用 | |
CN110448667A (zh) | 一种用于治疗椎间盘突出症的中药组合物及其制备方法和应用 | |
CN109601880A (zh) | 一种增加骨密度的保健食品 | |
CN104324319A (zh) | 一种促进骨关节健康的保健品 | |
CN117244030B (zh) | 一种具有养护关节功效的组合物、压片糖果及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |